Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

MannKind Corp (NASDAQ:MNKD)

0.95
Delayed Data
As of 4:00pm ET
 -0.021 / -2.16%
Today’s Change
0.64
Today|||52-Week Range
7.32
-34.48%
Year-to-Date
3 Billionaires Bet on MannKind Stock -- Should You Follow?
12:22pm / MotleyFool.com - Paid Partner Content
Better Buy: MannKind Corp. vs. Dexcom
May 20 / MotleyFool.com - Paid Partner Content
There Are Crazy Valuations, and Then There Are the Valuations of These 3 Stocks
May 23 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close0.97
Today’s open0.98
Day’s range0.95 - 0.99
Volume5,534,244
Average volume (3 months)6,278,353
Market cap$461.0M
Dividend yield--
Data as of 4:00pm ET, 05/31/2016

Growth & Valuation

Earnings growth (last year)-78.43%
Earnings growth (this year)+74.18%
Earnings growth (next 5 years)+26.80%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book--

Competitors

 Today’s
change
Today’s
% change
ENTAEnanta Pharmaceutica...+0.14+0.57%
ARRYArray Biopharma Inc+0.17+4.72%
XNPTXenoport Inc+0.05+0.71%
OMEROmeros Corp+0.28+2.45%
Data as of 4:00pm ET, 05/31/2016

Financials

Next reporting dateAugust 8, 2016
EPS forecast (this quarter)-$0.05
Annual revenue (last year)$0.00
Annual profit (last year)-$368.4M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
CEO, CFO, Director, VP &
Head-Investor Relations
Matthew J. Pfeffer
Chief Medical Officer
Raymond W. Urbanski
Corporate headquarters
Valencia, California

Forecasts

Partner Offers

Search for Jobs